To elucidate the clinical usefulness of PGE-MUM as a biomarker reflecting tumor burden, we focused on lung adenocarcinoma, known to express high COX-2 levels [6], and 54 patients were enrolled. Here, PTGS2 is linked to lung adenocarcinoma.